scholarly journals Compound heterozygous mutations in UBA5 causing early-onset epileptic encephalopathy in two sisters

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Gudny A. Arnadottir ◽  
Brynjar O. Jensson ◽  
Sigurdur E. Marelsson ◽  
Gerald Sulem ◽  
Asmundur Oddsson ◽  
...  
2015 ◽  
Vol 93 ◽  
pp. n/a-n/a
Author(s):  
D. Bonneau ◽  
G. Lenaers ◽  
V. Procaccio ◽  
P. Amati-Bonneau ◽  
P. Reynier

2018 ◽  
Vol 1 (4) ◽  
pp. 110
Author(s):  
Jiaying Shen

Very early onset inflammatory bowel disease (VEO-IBD), IBD diagnosed before 6 years of age, frequently presents with increased severity, aggressive progression, and often poor response to conventional treatments. Although the cause of IBD is generally considered to be intestinal immune dysfunction induced by polygenic mutations and environment and other factors, VEO-IBD has a stronger genetic susceptibility specifically the neonatal- or infantile-onset IBD. Herein we report compound heterozygous mutations in the tumor necrosis factor receptor superfamily member 13b (TNFRSF13B) gene in a 3-year-old male that was admitted to our hospital with lasted jaundice, repeated fever and diarrhea in May 2014 at 2-month-old. He was diagnosed with VEO-IBD based on clinical, laboratory and histopathological examination. However, he was unresponsive to the conventional therapy, including the nutritional support therapy, antibiotic and immunosuppressive treatment, and surgical release of neonatal intestinal obstruction. Novel compound heterozygous mutations, c.[365G>A];[452C>T](p.[R122Q];[P151L]), were discovered in TNFRSF13B, encoding TACI, for this patient.


Brain ◽  
2014 ◽  
Vol 137 (10) ◽  
pp. e301-e301 ◽  
Author(s):  
Dominique Bonneau ◽  
Estelle Colin ◽  
Florine Oca ◽  
Marc Ferré ◽  
Arnaud Chevrollier ◽  
...  

2018 ◽  
Author(s):  
Allison J Cox ◽  
Fillan Grady ◽  
Gabriel Velez ◽  
Vinit B Mahajan ◽  
Polly J Ferguson ◽  
...  

Compound heterozygotes occur when different mutations at the same locus on both maternal and paternal chromosomes produce a recessive trait. Here we present the tool VarCount for the quantification of mutations at the individual level. We used VarCount to characterize compound heterozygous coding variants in patients with epileptic encephalopathy and in the 1000 genomes participants. The Epi4k data contains variants identified by whole exome sequencing in patients with either Lennox-Gastaut Syndrome (LGS) or Infantile Spasms (IS), as well as their parents. We queried the Epi4k dataset (264 trios) and the phased 1000 genomes data (2504 participants) for recessive variants. To assess enrichment, transcript counts were compared between the Epi4k and 1000 genomes participants using minor allele frequency (MAF) cutoffs of 0.5% and 1.0%, and including all ancestries or only probands of European ancestry. In the Epi4k participants, we found enrichment for rare, compound heterozygous mutations in six genes, including three involved in neuronal growth and development; PRTG (p=0.00086, 1% MAF, combined ancestries), TNC (p=0.0221% MAF, combined ancestries), and MACF1 (p=0.0245, 0.5% MAF, EU ancestry). Due the total number of transcripts considered in these analyses, the enrichment detected was not significant after correction for multiple testing and higher powered or prospective studies are necessary to validate the candidacy of these genes. However, PRTG, TNC, and MACF1 are potential novel recessive epilepsy genes and our results highlight that compound heterozygous mutations should be considered in sporadic epilepsy.


Medicine ◽  
2019 ◽  
Vol 98 (5) ◽  
pp. e14228 ◽  
Author(s):  
Yu-Qing Fang ◽  
Fei Mao ◽  
Mei-Jia Zhu ◽  
Xiu-Hua Li

Sign in / Sign up

Export Citation Format

Share Document